Abstract: The invention relates to anionic oligosaccharide conjugates that may be used to mimic the structure and/or activity of the anionic bioactive molecules known as glycosaminoglycans (GAGs).

Abstract: The invention relates to anionic conjugates of glycosylated bacterial metabolites that may be used to mimic the structure and/or activity of the anionic bioactive molecules known as glycosaminoglycans (GAGs). The invention also relates to processes for the preparation of the conjugates. Such conjugates are useful in the prophylaxis and/or treatment of disease conditions and in particular chronic disease conditions such as inflammatory (including allergic) diseases, metastatic cancers and infection by pathogenic agents including bacteria, viruses or parasites.

Abstract: The present invention relates generally to the field of medicaments in the form of therapeutic molecules including inflammatory modulators and their design and selection. More specifically, the present invention relates to a target site on Interleukin 13 (IL-13) by which a GAG molecule or polyanionic glycoconjugate or anionic polysaccharide modulates IL-13 activity or function, said target site selected from the list consisting of amino acids located in the AB loops and/or helix D of human IL-13 or its homolog or derivative, and the use of said IL-13 target site to design a medicament for modulating physiological processes. Therapeutic and prophylactic compositions comprising the designed medicaments are also contemplated.